Northwestern Medicine investigators have discovered that a novel long noncoding RNA (lncRNA), which are usually 200 nucleotides longer than typical RNAs and are widely expressed in cells, could serve as a prognostic biomarker and therapeutic target for prostate cancer, according to a recent study published in Science Advances.
This article was originally published on MedicalXpress.com